Despite these positive studies, USP7 inhibitors may only stabilize wild-type TP53, whereas the majority of tumors harbor mutant TP53; therefore, the clinical efficacy of these inhibitors will depend on the genetic background of the tumor. This evidence concerns the gene TP53 and neoplasm.